Back to Browse Journals » Vascular Health and Risk Management » Volume 4 » Issue 4

Tobacco smoking cessation management: integrating varenicline in current practice

Authors Laurence M Galanti

Published Date September 2008 Volume 2008:4(4) Pages 837—845

DOI http://dx.doi.org/10.2147/VHRM.S3250

Published 5 September 2008

Laurence M Galanti

Clinique Universitaire UCL, Mont-Godinne, Yvoir, Belgium

Abstract: Tobacco smoking is widespread and is one of the world’s most prevalent modifiable risk factors for morbidity and mortality. It is important to facilitate smoking cessation better in order to reduce the health consequences of tobacco use. The most effective approach assisting smokers in their quit attempts combines both pharmacotherapy and nonpharmacological interventions. This review summarizes the latest international epidemiological data available on tobacco use, considers the associated effects on health, and reviews existing policies against tobacco use. Among the interventions for smoking cessation, the three major pharmacotherapies (which have demonstrated efficacy when combined with behavioral support) are discussed: nicotine replacement therapy (NRT), bupropion, and varenicline. As the newest pharmacotherapy made available in this area, particular consideration is given to varenicline, and a review of our clinical experience is offered.

Keywords: tobacco smoking cessation, nicotinic substitution, nicotine replacement therapy (NRT), bupropion, varenicline

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Epidemiology of yaws: an update

Kazadi WM, Asiedu KB, Agana N, Mitjà O

Clinical Epidemiology 2014, 6:119-128

Published Date: 2 April 2014

Relationship between interblink interval and dopamine

Lemon TI, Shah RD

Clinical Ophthalmology 2013, 7:793-794

Published Date: 29 April 2013

Application of magnetically induced hyperthermia in the model protozoan Crithidia fasciculata as a potential therapy against parasitic infections

Grazú V, Silber AM, Moros M, Asín L, Torres TE, Marquina C, Ibarra MR, Goya GF

International Journal of Nanomedicine 2012, 7:5351-5360

Published Date: 8 October 2012

Frontalis sling procedure for ocular myasthenia gravis

Asamura S, Kakizaki H, Enjyo M, Hashimoto T, Isogai N

Clinical Ophthalmology 2012, 6:575-577

Published Date: 12 April 2012

Comparison of Charlson comorbidity index with SAPS and APACHE scores for prediction of mortality following intensive care

Christensen S, Johansen M, Christiansen CF, Jensen R, Lemeshow S

Clinical Epidemiology 2011, 3:203-211

Published Date: 17 June 2011

Hyperhomocysteinemia decreases bone blood flow

Neetu Tyagi, Thomas P Vacek, John T Fleming, et al

Vascular Health and Risk Management 2011, 7:31-35

Published Date: 25 January 2011

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009